Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure–activity correlations with related alkaloids
(+)-1( R)-Coclaurine ( 1) and (−)-1( S)-norcoclaurine ( 3), together with quercetin 3- O-β- d-glucuronide ( 4), were isolated from the leaves of Nelumbo nucifera (Nymphaceae), and identified as anti-HIV principles. These compounds can serve as new leads for further development of anti-AIDS agents. (...
Gespeichert in:
Veröffentlicht in: | Bioorganic & medicinal chemistry 2005-01, Vol.13 (2), p.443-448 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | (+)-1(
R)-Coclaurine (
1) and (−)-1(
S)-norcoclaurine (
3), together with quercetin 3-
O-β-
d-glucuronide (
4), were isolated from the leaves of
Nelumbo nucifera (Nymphaceae), and identified as anti-HIV principles. These compounds can serve as new leads for further development of anti-AIDS agents.
(+)-1(
R)-Coclaurine (
1) and (−)-1(
S)-norcoclaurine (
3), together with quercetin 3-
O-β-
d-glucuronide (
4), were isolated from the leaves of
Nelumbo nucifera (Nymphaceae), and identified as anti-HIV principles. Compounds
1 and
3 demonstrated potent anti-HIV activity with EC
50 values of 0.8 and 125 and >25, respectively. Compound
4 was less potent (EC
50 2
μg/mL). In a structure–activity relationship study, other benzylisoquinoline, aporphine, and bisbenzylisoquinoline alkaloids, including liensinine (
14), negferine (
15), and isoliensinine (
16), which were previously isolated from the leaves and embryo of
Nelumbo nucifera, were evaluated for anti-HIV activity. Compounds
14–16 showed potent anti-HIV activities with EC
50 values of 9.9, >8.6, and >6.5, respectively. Nuciferine (
12), an aporphine alkaloid, had an EC
50 value of 0.8
μg/mL and TI of 36. In addition, synthetic coclaurine analogs were also evaluated. Compounds
1,
3,
12, and
14–
16 can serve as new leads for further development of anti-AIDS agents. |
---|---|
ISSN: | 0968-0896 1464-3391 |
DOI: | 10.1016/j.bmc.2004.10.020 |